JP2014515407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515407A5 JP2014515407A5 JP2014513785A JP2014513785A JP2014515407A5 JP 2014515407 A5 JP2014515407 A5 JP 2014515407A5 JP 2014513785 A JP2014513785 A JP 2014513785A JP 2014513785 A JP2014513785 A JP 2014513785A JP 2014515407 A5 JP2014515407 A5 JP 2014515407A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- bonds
- pharmaceutical formulation
- divalent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 32
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- -1 triphenylphosphonium cation Chemical group 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 9
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 9
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 229950010033 ebselen Drugs 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 9
- 235000010384 tocopherol Nutrition 0.000 claims description 9
- 229960001295 tocopherol Drugs 0.000 claims description 9
- 229930003799 tocopherol Natural products 0.000 claims description 9
- 239000011732 tocopherol Substances 0.000 claims description 9
- 229940035936 ubiquinone Drugs 0.000 claims description 9
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 8
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 15
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims 5
- 125000003277 amino group Chemical group 0.000 claims 5
- 150000001450 anions Chemical class 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 150000001768 cations Chemical class 0.000 claims 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 150000002430 hydrocarbons Chemical group 0.000 claims 5
- 150000002500 ions Chemical class 0.000 claims 5
- 125000000468 ketone group Chemical group 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 0 CC(C(c1cc(*)c(*)cc11)=O)=CC1=O Chemical compound CC(C(c1cc(*)c(*)cc11)=O)=CC1=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161492940P | 2011-06-03 | 2011-06-03 | |
| US61/492,940 | 2011-06-03 | ||
| PCT/US2012/040711 WO2012167236A1 (en) | 2011-06-03 | 2012-06-04 | Oral formulations of mitochondrially-targeted antioxidants and their preparation and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017196849A Division JP6461276B2 (ja) | 2011-06-03 | 2017-10-10 | ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515407A JP2014515407A (ja) | 2014-06-30 |
| JP2014515407A5 true JP2014515407A5 (enExample) | 2015-07-02 |
| JP6448366B2 JP6448366B2 (ja) | 2019-01-09 |
Family
ID=47259946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513785A Active JP6448366B2 (ja) | 2011-06-03 | 2012-06-04 | ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用 |
| JP2017196849A Active JP6461276B2 (ja) | 2011-06-03 | 2017-10-10 | ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017196849A Active JP6461276B2 (ja) | 2011-06-03 | 2017-10-10 | ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9192676B2 (enExample) |
| EP (1) | EP2714024B1 (enExample) |
| JP (2) | JP6448366B2 (enExample) |
| CN (1) | CN103764132B (enExample) |
| AU (1) | AU2012261854B2 (enExample) |
| BR (1) | BR112013030605A2 (enExample) |
| CA (1) | CA2837437C (enExample) |
| EA (1) | EA031399B1 (enExample) |
| ES (1) | ES2704064T3 (enExample) |
| WO (1) | WO2012167236A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012261854B2 (en) * | 2011-06-03 | 2017-11-16 | Mitotech Sa | Oral formulations of mitochondrially-targeted antioxidants and their preparation and use |
| JP6506177B2 (ja) * | 2013-01-22 | 2019-04-24 | ミトテック ソシエテ アノニム | ミトコンドリアにターゲティングされた抗酸化剤を含む医薬処方物 |
| WO2015063553A2 (en) * | 2013-04-11 | 2015-05-07 | Mitotech S.A. | Mitochondrially-targeted timoquinones and toluquinones |
| EP3116470B1 (en) | 2014-02-25 | 2019-05-08 | Mitotech SA | Cosmetic compositions of mitochondrially targeted antioxidants |
| WO2019139831A1 (en) * | 2018-01-10 | 2019-07-18 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate |
| US20230038070A1 (en) * | 2019-12-10 | 2023-02-09 | Mitotech S.A. | Polymer matrixes for different compositions of mitochondrially targeted antioxidants |
| CN116194100A (zh) * | 2020-04-03 | 2023-05-30 | 米拓科技有限公司 | 线粒体靶向抗氧化剂在治疗严重炎症中的用途 |
| CN114344274A (zh) * | 2022-01-05 | 2022-04-15 | 盖茨汉普(武汉)植物应用研究有限公司 | 一种Mitoq抗氧化硬胶囊配方及制备工艺 |
| WO2025078880A1 (en) * | 2023-10-11 | 2025-04-17 | Mitotech S.A. | Mitochondria-targeted antioxidants for use in the treatment of cell balloooning-associated diseases, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5538974A (en) | 1994-01-27 | 1996-07-23 | Senju Pharamceutical Co., Ltd. | Ophthalmic composition for lowering intraocular pressure |
| US6331532B1 (en) | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
| EP1047701B1 (en) | 1997-11-25 | 2005-05-25 | Antipodean Biotechnology Limited | Mitochondrially targeted antioxidants |
| US20080275005A1 (en) | 1998-11-25 | 2008-11-06 | Murphy Michael P | Mitochondrially targeted antioxidants |
| US20070270381A1 (en) | 2000-05-25 | 2007-11-22 | Antipodean Pharmaceuticals, Inc. | Mitochondrially targeted antioxidants |
| US20020044913A1 (en) | 2000-02-11 | 2002-04-18 | Hamilton Nathan D. | Cosmetics to support skin metabolism |
| ITRM20010755A1 (it) | 2001-12-20 | 2003-06-20 | Simonelli Giuseppe | Uso del chinone q10 per il trattamento delle malattie oculari. |
| US6984636B2 (en) | 2002-08-12 | 2006-01-10 | Medical Research Council | Mitochondrially targeted antioxidants |
| CA2583087C (en) | 2003-09-19 | 2012-07-10 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| WO2006005759A2 (en) | 2004-07-13 | 2006-01-19 | Oridis Biomed Forschungs- Und Entwicklungs Gmbh | Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| EP1785138A1 (en) | 2004-08-30 | 2007-05-16 | Kaneka Corporation | Mitochondria activators |
| RU2318500C2 (ru) | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
| WO2008048135A1 (fr) | 2006-10-20 | 2008-04-24 | Limited Liability Company 'mitotechnology' | Composition destinée à la régénération, la stimulation de la croissance et l'adaptation de plantes à tous types de facteurs de stress |
| WO2008048134A1 (en) | 2006-10-20 | 2008-04-24 | Limited Liability Company 'mitotechnology' | Pharmaceutical compositions for preventing and treating eye pathologies |
| US9427444B2 (en) * | 2007-01-29 | 2016-08-30 | Mitotech Sa | Pharmaceutical and cosmetic compositions for accelerated healing of wounds and other surface damages |
| WO2008127138A1 (fr) * | 2007-04-11 | 2008-10-23 | Limited Liability Company 'mitotechnology' | Composition visant à ralentir le vieillissement et à allonger la durée de vie de l'organisme et utilisation de cette composition |
| WO2009005386A1 (en) | 2007-06-29 | 2009-01-08 | Limited Liability Company 'mitotechnology' | Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases |
| US8716486B2 (en) | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| JP2012525397A (ja) | 2009-04-28 | 2012-10-22 | エジソン ファーマシューティカルズ， インコーポレイテッド | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| EA025414B1 (ru) * | 2009-06-10 | 2016-12-30 | Общество С Ограниченной Ответственностью "Митотех" | Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии |
| AU2009355359B2 (en) * | 2009-11-13 | 2016-11-10 | Mitotech S.A. | Pharmaceutical substances on the basis of mitochondrially addressed antioxidants |
| AU2012261854B2 (en) * | 2011-06-03 | 2017-11-16 | Mitotech Sa | Oral formulations of mitochondrially-targeted antioxidants and their preparation and use |
-
2012
- 2012-06-04 AU AU2012261854A patent/AU2012261854B2/en not_active Ceased
- 2012-06-04 BR BR112013030605A patent/BR112013030605A2/pt not_active Application Discontinuation
- 2012-06-04 WO PCT/US2012/040711 patent/WO2012167236A1/en not_active Ceased
- 2012-06-04 EP EP12792111.2A patent/EP2714024B1/en active Active
- 2012-06-04 CN CN201280027129.0A patent/CN103764132B/zh not_active Expired - Fee Related
- 2012-06-04 US US14/123,311 patent/US9192676B2/en active Active
- 2012-06-04 CA CA2837437A patent/CA2837437C/en active Active
- 2012-06-04 ES ES12792111T patent/ES2704064T3/es active Active
- 2012-06-04 EA EA201301321A patent/EA031399B1/ru not_active IP Right Cessation
- 2012-06-04 JP JP2014513785A patent/JP6448366B2/ja active Active
-
2015
- 2015-10-20 US US14/887,406 patent/US9572890B2/en active Active
-
2017
- 2017-10-10 JP JP2017196849A patent/JP6461276B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515407A5 (enExample) | ||
| US20220071929A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP6462045B2 (ja) | スルフォラファンの単離及び精製 | |
| JP2009102342A5 (enExample) | ||
| JP2015530382A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2016534063A5 (enExample) | ||
| JP2013511496A5 (enExample) | ||
| JP2013545730A5 (enExample) | ||
| JP2015515992A5 (enExample) | ||
| JP2020517727A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| NZ703564A (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2016516772A (ja) | オキサシクロヘプタン及びオキサビシクロヘプテンの配合物 | |
| JP2013519653A5 (enExample) | ||
| JP2016516773A5 (enExample) | ||
| JP2018520198A5 (enExample) | ||
| US9713597B2 (en) | Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone | |
| JP2011046708A5 (enExample) | ||
| CN104244936A (zh) | 镇痛剂 | |
| BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
| CN113101289A (zh) | 烟酰胺在制备治疗手足皮肤反应制剂中的应用 | |
| RU2018130097A (ru) | Лечение экземы кистей | |
| RU2016110546A (ru) | Комбинированная лекарственная терапия |